. Author manuscript; available in PMC: 2014 Jun 1.

Published in final edited form as: Drug Deliv Transl Res. 2012 Dec 12;3(3):260–271. doi: 10.1007/s13346-012-0119-6

Table II.

Plasma compartmental pharmacokinetic parameter estimates for PAMAM-OH dendrimers and HPMA copolymers.

Parameter	G5.0-OH (29 kDa)	G6.0-OH (58 kDa)	G7.0-OH (117 kDa)	HPMA copolymer (26 kDa)	HPMA copolymer (52 kDa)	HPMA copolymer (131 kDa)
Clearance (mL/h)
Elimination Clearance (E.CL)	10.50 ± 1.30	5.00 ± 1.00	0.79 ± 0.21	7.24 ± 0.58	6.02 ± 0.82	0.17 ± 0.03
Renal Clearance (CL_R)	0.266	0.087	0.007	1.179	0.807	0.041
Dose normalized Exposure
AUC_{plasma(0–24h)} (mg.h/mg.mL)	0.1 ± 0.01	0.2 ± 0.04	1.27 ± 0.34	0.14 ± 0.01	0.13 ± 0.02	5.88 ± 0.97
AUC_{tumor(0–168h)} (mg.h/mg.g)	0.48	0.82	7.99	0.21	0.23	3.48
AUC_tumor/AUC_plasma	5.06	4.12	6.31	1.52	1.70	0.59

Elimination clearance and plasma exposure were computed by two-compartmental analysis with bolus input. Renal clearances were computed from urine data. Tumor AUCs were computed from area under the tumor concentration profile curve. Data is presented as mean ± standard error.